A clearer view of what comes next. Virtual credits. Real-world intelligence.
OdinSignal
← All articles

ODINSIGNAL JOURNAL · NEWS & EVENTS

FDA Decision on D‑PLEX100 Scheduled for 28 Nov 2026

The FDA’s PDUFA deadline for D‑PLEX100, a surgical‑site infection preventive, is set for 28 Nov 2026. Follow updates on OdinSignal.

OdinSignal science editorial poster: FDA Decision on D‑PLEX100 Scheduled for 28 Nov 2026
OdinSignal editorial design with an AI-generated illustrative background; not event photography.

At a glance

Event
D-PLEX100 - prevention of surgical site infections
Date
2026-11-28
Participants
FDA

The FDA’s PDUFA calendar lists a decision deadline for the antimicrobial polymer D‑PLEX100 on 28 Nov 2026. The entry appears under the PYPD ticker as “PYPD Micro D‑PLEX100 – prevention of surgical site infections · PDUFA 2026‑11‑28” on the independent PDUFA calendar. This date marks the agency’s deadline to either approve the product or issue a complete response letter. As of today the outcome remains pending, and the decision will determine whether D‑PLEX100 gains market authorization for preventing surgical‑site infections. Stakeholders will be watching the FDA’s assessment closely, given the potential impact on infection control in operative settings. No time, venue, or additional details have been disclosed.

Follow the event on OdinSignal for real‑time updates.

FOLLOW THE EVENT

What happens next?

Explore the event, review its rules, and share your prediction on OdinSignal.

Explore the prediction market →Virtual credits only. No cash value.

More from the Journal

Prediction markets express uncertainty, not established outcomes. OdinSignal uses virtual credits with no cash value.